Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of NASH. For more information, visit www.madrigalpharma.com.

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

In the ESSENCE trial, semaglutide improved liver fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH).

Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

Liver disease affects an estimated 1.5 billion people worldwide, with many cases going undiagnosed until it's too late. As liver ...

Conshohocken’s Madrigal Pharmaceuticals, saw third-quarter sales soar for its NASH treatment, Rezdiffra, writes John George ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

Fatty liver disease happens when fat builds up in your liver. This can cause damage, inflammation, and other complications.

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...

Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.